open access

Vol 88, No 6 (2020)
Case report
Submitted: 2020-11-20
Accepted: 2020-12-18
Published online: 2020-12-22
Get Citation

SARS-CoV-2 lung disease in a patient with pulmonary sarcoidosis — case report

Lucyna Magdalena Opoka1, Dorota Wyrostkiewicz2, Jolanta Winek3, Katarzyna Błasińska4, Joanna Miłkowska-Dymanowska4, Monika Szturmowicz2
DOI: 10.5603/ARM.a2020.0199
·
Pubmed: 33393657
·
Adv Respir Med 2020;88(6):620-625.
Affiliations
  1. Department of Radiology, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland
  2. 1st Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland
  3. Outpatients’ Clinic, National Tuberculosis and Lung Diseases Research Institute, Outpatients’ Clinic, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland
  4. Department of Pneumonology and Allergology, Medical University, Lodz, Poland

open access

Vol 88, No 6 (2020)
CASE REPORTS
Submitted: 2020-11-20
Accepted: 2020-12-18
Published online: 2020-12-22

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the recently identified cause of the current pandemic. In patients with chronic respiratory lung diseases, SARS-CoV-2 may result in significant morbidity and increased mortality. We present a case of a 69-year-old male with stage II pulmonary sarcoidosis who had been under observation for 30 months without immunosuppressive treatment. He then developed severe SARS-CoV-2 disease with typical radiological and laboratory findings. Therapy with oxygen, antibiotics, low-molecular-weight heparin in a prophylactic dose, and dexamethasone resulted in marked clinical improvement. We will discuss the rationale for corticosteroid use in both SARS-CoV-2 disease and in SARS-CoV-2 disease that is complicating comorbid sarcoidosis.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the recently identified cause of the current pandemic. In patients with chronic respiratory lung diseases, SARS-CoV-2 may result in significant morbidity and increased mortality. We present a case of a 69-year-old male with stage II pulmonary sarcoidosis who had been under observation for 30 months without immunosuppressive treatment. He then developed severe SARS-CoV-2 disease with typical radiological and laboratory findings. Therapy with oxygen, antibiotics, low-molecular-weight heparin in a prophylactic dose, and dexamethasone resulted in marked clinical improvement. We will discuss the rationale for corticosteroid use in both SARS-CoV-2 disease and in SARS-CoV-2 disease that is complicating comorbid sarcoidosis.

Get Citation

Keywords

SARS-CoV-2; sarcoidosis; corticosteroids; anticoagulation; computed tomography

About this article
Title

SARS-CoV-2 lung disease in a patient with pulmonary sarcoidosis — case report

Journal

Advances in Respiratory Medicine

Issue

Vol 88, No 6 (2020)

Article type

Case report

Pages

620-625

Published online

2020-12-22

DOI

10.5603/ARM.a2020.0199

Pubmed

33393657

Bibliographic record

Adv Respir Med 2020;88(6):620-625.

Keywords

SARS-CoV-2
sarcoidosis
corticosteroids
anticoagulation
computed tomography

Authors

Lucyna Magdalena Opoka
Dorota Wyrostkiewicz
Jolanta Winek
Katarzyna Błasińska
Joanna Miłkowska-Dymanowska
Monika Szturmowicz

References (18)
  1. Southern BD. Patients with interstitial lung disease and pulmonary sarcoidosis are at high risk for severe illness related to COVID-19. Cleve Clin J Med. 2020 [Epub ahead of print].
  2. Monpara JD, Sodha SJ, Gupta PK. COVID-19 associated complications and potential therapeutic targets. Eur J Pharmacol. 2020; 886: 173548.
  3. Jeny F, Lhote R, Lorillon G, et al. Correspondence on 'glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis'. Ann Rheum Dis. 2020 [Epub ahead of print].
  4. Morgenthau AS, Levin MA, Freeman R, et al. Moderate or severe impairment in pulmonary function is associated with mortality in sarcoidosis patients infected with SARS‑CoV‑2. Lung. 2020; 198(5): 771–775.
  5. Baughman RP, Drent M. The treatment of pulmonary sarcoidosis. In: M.A. Judson (ed). Pulmonary sarcoidosis: a guide for the practicing clinician. Respiratory Medicine 27. Springer Science+Bussiness Media, New York 2014: 41–64.
  6. Elicker BM, Kallianos KG, Henry TS. The role of high-resolution computed tomography in the follow-up of diffuse lung disease: Number 2 in the Series "Radiology" Edited by Nicola Sverzellati and Sujal Desai. Eur Respir Rev. 2017; 26(144).
  7. Panselinas E, Judson MA. Acute pulmonary exacerbation of sarcoidosis. In: M.A. Judson (ed). Pulmonary sarcoidosis: a guide for the practicing clinician. Respiratory Medicine 27. Springer Science+Bussiness Media, New York 2014: 65–78.
  8. Baughman RP, Lower EE. Frequency of acute worsening events in fibrotic pulmonary sarcoidosis patients. Respir Med. 2013; 107(12): 2009–2013.
  9. Roberto G, Roberta F, Paola BM, et al. Coronavirus disease 2019 (COVID-19) in Italy: features on chest computed tomography using a structured report system. Sci Rep. 2020; 10(1): 17236.
  10. Fu F, Lou J, Xi D, et al. Chest computed tomography findings of coronavirus disease 2019 (COVID-19) pneumonia. Eur Radiol. 2020; 30(10): 5489–5498.
  11. Kanne JP, Little BP, Chung JH, et al. Essentials for radiologists on COVID-19: an update- scientific expert panel. Radiology. 2020; 296(2): E113–E114.
  12. Piazza G, Campia U, Hurwitz S, et al. Registry of arterial and venous thromboembolic complications in patients with COVID-19. J Am Coll Cardiol. 2020; 76(18): 2060–2072.
  13. Flisiak R, Parczewski M, Horban A, et al. Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists. Annex no. 2 as of October 13, 2020. Pol Arch Intern Med. 2020; 130(10): 915–918.
  14. Taccone FS, Gevenois PA, Peluso L, et al. Higher intensity thromboprophylaxis regimens and pulmonary embolism in critically ill coronavirus disease 2019 patients. Crit Care Med. 2020; 48(11): e1087–e1090.
  15. Monreal E, Sainz de la Maza S, Natera-Villalba E, et al. High versus standard doses of corticosteroids in severe COVID-19: a retrospective cohort study. Eur J Clin Microbiol Infect Dis. 2020 [Epub ahead of print].
  16. Cano EJ, Fuentes XF, Campioli CC, et al. Impact of corticosteroids in coronavirus disease 2019 outcomes: systematic review and meta-analysis. Chest. 2020 [Epub ahead of print].
  17. Györfi AH, Kopp M, May M, et al. Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis. Ann Rheum Dis. 2020 [Epub ahead of print].
  18. Sweiss NJ, Korsten P, Syed HJ, et al. When the Game Changes: Guidance to Adjust Sarcoidosis Management During the Coronavirus Disease 2019 Pandemic. Chest. 2020; 158(3): 892–895.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl